- Email: [email protected]
Involvement of exosomes in dopaminergic neurodegeneration by microglial activation in midbrain slice cultures
Biochemical and Biophysical Research Communications 511 (2019) 427e433
Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc
Involvement of exosomes in dopaminergic neurodegeneration by microglial activation in midbrain slice cultures Reiho Tsutsumi a, Yuria Hori a, Takahiro Seki a, *, Yuki Kurauchi a, Masahiro Sato a, Mutsumi Oshima a, Akinori Hisatsune b, c, Hiroshi Katsuki a a
Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan Priority Organization for Innovation and Excellence, Kumamoto University, Kumamoto, Japan Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program”, Kumamoto University, Kumamoto, Japan b c
a r t i c l e i n f o
a b s t r a c t
Article history: Received 8 February 2019 Accepted 14 February 2019 Available online 23 February 2019
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive degeneration of dopamine neurons in the substantia nigra. Microglial activation is frequently observed in the brains of patients with PD and animal models. Interferon-g (IFN-g)/lipopolysaccharide (LPS) treatment triggers microglial activation and the reduction of dopamine neurons in midbrain slice cultures. We have previously reported that nitric oxide (NO) is mainly involved in this dopaminergic degeneration. However, this degeneration was not completely suppressed by the inhibition of NO synthesis, suggesting that factors other than NO also contribute to dopaminergic neurodegeneration. Exosomes are extracellular vesicles with diameters of 40e200 nm that contain various proteins and micro RNAs and are regarded as a novel factor that mediates cell-to-cell interactions. Previous studies have demonstrated that exosome release is enhanced by microglial stimulation and that microglia-derived exosomes increases neuronal apoptosis. In the present study, we investigated whether exosomes are involved in dopaminergic neurodegeneration triggered by microglial activation in midbrain slice cultures. IFN-g/LPS treatment to the midbrain slice cultures activated microglia, increased exosomal release, and decreased dopamine neurons. GW4869, an inhibitor of a neutral sphingomyelinase 2, decreased exosomal release and significantly prevented dopaminergic neurodegeneration by IFN-g/LPS without affecting NO production. In contrast, D609, an inhibitor of sphingomyelin synthase and NO synthase, did not affect dopaminergic neurodegeneration, although it strongly inhibited NO production. The protective effect mediated by inhibition of NO synthase would be counteracted by enhanced exosomal release caused by D609 treatment. In addition, dopaminergic neurodegeneration is triggered by the treatment of exosomes isolated from culture media of IFN-g/LPS-treated slices. These results suggest that exosomes are involved in dopaminergic neurodegeneration by microglial activation. © 2019 Elsevier Inc. All rights reserved.
Keywords: Parkinson's disease Dopamine neuron Microglia Exosomes
1. Introduction Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by severe motor dysfunctions such as bradykinesia, resting tremor, and rigidity [1,2]. These dysfunctions are caused by the progressive and selective degeneration of dopamine neurons in the midbrain substantia nigra pars compacta (SNpc)
* Corresponding author. Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 OeHonmachi, Chuo-ku, Kumamoto, 862-0973, Japan. E-mail address: [email protected] (T. Seki). https://doi.org/10.1016/j.bbrc.2019.02.076 0006-291X/© 2019 Elsevier Inc. All rights reserved.
[1e3]. Although various environmental and genetic factors are reported to be involved in PD pathogenesis [1e3], it has not been fully elucidated how the dopamine neurons are selectively degenerated in PD. Inflammation is considered to be involved in dopaminergic neurodegeneration because the accumulation of reactive microglia frequently occurs in the SNpc of patients with PD [4,5]. 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin specific for dopamine neurons, reduces dopamine neurons in SNpc, and induces the motor dysfunction like parkinsonism of PD patients in mice and rats [6]. MPTP treatment induces the accumulation of activated microglia in SNpc [7], and the neurotoxic effect of MPTP is
428
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
reduced by the inhibition of microglial activation [8]. We have previously demonstrated that microglial activation by interferon-g (IFN-g) and lipopolysaccharide (LPS) induced dopaminergic degeneration in the SNpc of midbrain slice cultures [9]. Nitric oxide (NO), generated from the activated microglia, contributes to the dopaminergic neurodegeneration, because an inhibitor of nitric oxide synthase (NOS) significantly prevented this degeneration [9]. However, although the NOS inhibitor almost completely blocked NO synthesis from the activated microglia, it did not completely prevent dopaminergic neurodegeneration. Therefore, it is possible that other factors in addition to NO contribute to dopaminergic neurodegeneration by microglial activation. Exosomes are extracellular vesicles with diameters of 40e200 nm, which contain various proteins and micro RNAs (miRNAs) and participate in intercellular communication [10]. Notably, exosomes are considered to be involved in neuron-glia communication in the brain [11]. Exosomes are elevated in the cerebrospinal fluids of patients with PD [12]. In addition, microglial activation increases exosome release from MG6 microglial cells [13]. Moreover, exosomes from a-synuclein-treated microglial cells have a cytotoxic effect when added to primary cultured neural cells [14]. Taken together, we predicted that exosomes from the activated microglia contribute to dopaminergic neurodegeneration in the midbrain slice cultures. To validate this hypothesis, we investigated the effects of the chemicals that affect the production of exosomes in dopaminergic neurodegeneration induced by microglial activation. 2. Materials and methods 2.1. Preparation of midbrain slice cultures All animal experimental procedures were approved by the Kumamoto University Ethics Committee on Animal Experiments, and animals were handled according to the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and to reduce the number of animals used. Organotypic slice cultures of the rat midbrain were prepared as described in our previous studies [15,16]. Briefly, coronal midbrain slices (350-mm thick) were prepared from 2 or 3 day-old neonatal Wistar rats (Nihon SLC, Shizuoka, Japan) and were transferred onto microporous membranes (Millicell-CM, Merck Millipore, Darmstadt, Germany) in six-well plates. Culture medium, consisting of 50% minimum essential medium/HEPES, 25% Hanks' balanced salt solution and 25% heat-inactivated horse serum supplemented with 6.5 mg/mL glucose, 2 mM L-glutamine, and 10 U/mL penicillin-G plus 10 mg/mL streptomycin, was supplied at a volume of 0.7 mL per well. The culture medium was exchanged with fresh medium on the next day of culture preparation, and thereafter, every 3 day. Slices were maintained in a 34 C, 5% CO2 humidified atmosphere for 20 days in vitro (DIV). For immunohistochemistry experiments, slices were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer containing 4% sucrose at 4 C for 2.5 h. Culture media samples were collected for exosome isolation and nitrite quantification.
were simultaneously treated with IFN-g and LPS for 96 h. 2.3. Isolation and detection of exosomes from the culture media Isolation of exosomes was conducted following a modified method from a previous report [17]. Culture media from 3 to 6 independent experiments were centrifuged at 2000g for 10 min at 4 C to precipitate the cell debris. The supernatant was collected and filtrated through a 0.2 mm filter to remove particles larger than 220 nm. The filtered supernatant was ultracentrifuged at 100,000g for 70 min at 4 C using an Avanti HP-30I (Beckman Coulter, Brea, CA, USA) to precipitate the exosomes. After removing the supernatant, pellets were resuspended in PBS and ultracentrifuged at 100,000g for 70 min at 4 C. For immunoblotting, the pellets were resuspended in sample buffer containing 0.5 M of Tris-HCl (pH 6.8), 10% SDS, 5 mM of dithiothreitol, 10% glycerol, and 1% bromophenol blue, followed by heating at 100 C for 15 min. For treatment of the other slices, the pellets were resuspended in serum-free culture media. Exosomes from 9 wells of culture media from control condition (exosome-C) or IFN-g/LPS-treated culture media (exosome-I/L) were added to the other slice cultures for 72 h (from DIV 18e20). 2.4. Immunohistochemistry Immunohistochemical examinations were performed according to previously described methods [15,16]. Cultured slices were incubated for 1 h at room temperature with PBS containing 0.3% Triton X-100 and 3% normal donkey serum for permeabilization and blocking. Thereafter, slices were incubated overnight at 4 C with a primary antibody solution in PBS containing 0.3% Triton X100 and 3% normal donkey serum. Primary antibodies were antityrosine hydroxylase (TH) mouse monoclonal antibody (1:500; Millipore, Burlington, MA, USA), anti-TH rabbit polyclonal antibody (1:500; Millipore), anti-Iba 1 rabbit polyclonal antibody (1:400; H070e47; Wako Chemicals, Osaka, Japan), anti-glial fibrillary acidic protein (GFAP) goat polyclonal antibody (1:500, Santa Cruz Biotechnology, Dallas, TX, USA), and anti-iNOS mouse monoclonal antibody (1:500, BD Biosciences, San Jose, CA, USA). After 3 washes with PBS, slices were incubated for 1 h at room temperature in Alexa Fluor 488- or Alexa Fluor 555-conjugated secondary antibodies (1:500; Thermo Fisher Scientific) in PBS containing 0.3% Triton X-100 and 3% normal donkey serum. Fluorescent images of immunostained slices were obtained using a fluorescence microscope (BIOREVO, Keyence, Osaka, Japan) or a confocal laser microscope (TCS SP5, Leica Biosystems, Nussloch, Germany). Immunoreactivities of Iba 1 and iNOS in fluorescent images were quantified using LAS AF Lite software (Leica Biosystems). 2.5. Immunoblotting Equal volumes of exosomal lysates were subjected to SDS-PAGE, followed by immunoblot analyses as described in our previous study [18] using anti-CD63 mouse monoclonal antibody (1:500; Bio-Rad Laboratories, Hercules, CA, USA) and anti-flotillin-2 mouse monoclonal antibody (1:1000; BD Biosciences).
2.2. Drug treatment 2.6. Nitrite quantification Rat interferon (IFN)-g (PeproTech, Rocky Hill, NJ, USA) and LPS (from Escherichia coli, serotype 0111; B4; Sigma, St Louis, MO, USA) were used to activate microglia in slice cultures [15]. From DIV 17e20, midbrain slice cultures were treated with IFN-g (50 ng/mL) for 24 h, followed by LPS (10 ng/mL) treatment for 72 h. GW4869 (1 or 10 mM, Sigma), an inhibitor of neutral sphingomyelinase 2, and D609 (10 or 50 mM, Sigma), an inhibitor of sphingomyelin synthase,
A colorimetric Griess assay was employed to determine the concentration of nitrite in the culture medium, which reflects the amount of NO released from cultured tissues. Culture supernatants were reacted with an equal volume of Griess reagent (Sigma) for 10 min at room temperature, and the amount of diazonium compound was determined based on the absorbance at a wavelength of
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
560 nm. 2.7. Statistical analyses All quantitative data are represented as the mean ± SEM. Statistical differences were determined by one-way ANOVA, followed by a post hoc test (Tukey method). Probability values less than 0.05 were considered significant. 3. Results and discussion Exosomes are known to be released from both neurons and glial cells and to be involved in neuron-glia communication [11]. We first examined whether inflammatory stimulation affected exosomal release in midbrain slice cultures. Treatment with IFN-g and LPS prominently increased exosome marker levels (CD63 and flotillin-2) in exosomal lysates from the culture media of midbrain slice cultures (Fig. 1A). This treatment induced microglial activation, which was characterized by increased Iba1 immunoreactivity and morphological changes of microglia to amoeboid shapes in midbrain slice cultures (Fig. 1B), consistent with our previous study
Fig. 1. IFN-g/LPS treatment triggers exosome release and microglial activation in rat midbrain slice cultures. A. Immunoblot analysis of exosomal markers (CD63 and flotillin-2) in isolated exosomal lysates from the culture media of midbrain slice cultures. Slices were cultured under the control conditions or treated with 50 ng/mL IFN-g for 24 h followed by 10 mg/mL LPS for 72 h. B, C. Representative images of Iba 1 (B) and GFAP (C) immunoreactivities on the cultured midbrain slices. Slices were cultured under control conditions or treated with IFN-g/LPS. Scale bars, 50 mm.
429
[9]. On the other hand, GFAP immunoreactivity was not affected by IFN-g/LPS (Fig. 1C). Although astrocytes also express toll-like receptor 4 (TLR4), a receptor for LPS, the level of TLR4 is lower in astrocytes than in microglia [19]. Taken together, astrocytes were not activated by these stimuli. In addition, minocycline, which inhibits microglial activation, decreased the level of exosomal markers (Supplemental Fig. 1A). Taken together, although we could not exclude the possibility that an increase in exosomes partly comes from neurons, we found that treatment of midbrain slice cultures with IFN-g/LPS resulted in an increase in exosomal release, mainly from the activated microglia. This is consistent with a previous report that stimulation with exogenous ATP triggers an increase in exosomal release from MG6 cells, a cell line derived from microglia [13]. We next examined the effects of pharmacological alteration of exosomal release on IFN-g/LPS-induced dopaminergic neurodegeneration. Exosomal production is regulated by ceramide synthesis in multivesicular bodies [20]. G4869 is an inhibitor of neutral sphingomyelinase 2, which decreases ceramide synthesis from sphingomyelin and inhibits the production and release of exosomes [20]. We simultaneously treated midbrain slice cultures with GW4869 (1 or 10 mM) and IFN-g/LPS to examine dopaminergic neurodegeneration in the SNpc. Tyrosine hydroxylase (TH)-positive dopamine neurons in SNpc were significantly decreased after treatment with IFN-g/LPS (Fig. 2A and B), consistent with our previous studies [9]. Concomitant treatment of GW4869 significantly prevented the reduction of dopamine neurons by IFN-g/LPS (Fig. 2A and B). IFN-g/LPS-triggered production of nitric oxide (NO) was not significantly affected by GW4869, whereas treatment with 10 mM GW4869 slightly decreased this production (Fig. 2C). On the other hand, exosomal release to the culture media was strikingly impaired by GW4869 (Fig. 2D). Because inhibition of microglial activation by minocycline decreased exosomal release and dopaminergic neurodegeneration triggered by IFN-g/LPS (Supplemental Fig. 2), the inhibition of dopaminergic neurodegeneration by GW4869 might be caused by an inhibition of microglial activation. However, the elevated immunoreactivity of Iba 1 and the morphological changes in Iba 1-positive microglia by IFN-g/LPS treatment were not affected by GW4869 (Fig. 2E, G). Likewise, the elevated immunoreactivity of inducible nitric oxide synthase (iNOS), a marker of inflammatory activation of microglia, were not affected by GW4869 (Fig. 2F, H). In addition, GW4869 prevented exosomal release to the culture media, but did not affect the elevation of inflammatory cytokine mRNAs in a microglial cell line (BV2 cells) (Supplemental Fig. 1), suggesting that GW4869 did not inhibit microglial activation through IFN-g/LPS. Another possibility is that GW4869 directly affects neurons to protect cells from inflammatory stimuli. However, we found that GW4869 triggered a significant decrease of TH-positive dopamine neurons in midbrain primary cultures (Supplemental Fig. 3). These findings suggest that the protective effect of GW4869 on dopamine neurons is mediated by the prevention of exosomal release from activated microglia. To further investigate the involvement of exosomes in dopaminergic neurodegeneration induced by microglial activation, we examined the effect of a chemical that enhances exosomal release. D609 is an inhibitor of sphingomyelin synthase, which catalyzes the conversion of ceramide to sphingomyelin, induces the accumulation of ceramide, and enhances the production and release of exosomes [21]. Concomitant treatment of D609 (10 or 50 mM) with IFN-g/LPS neither prevented nor exacerbated the dopaminergic neurodegeneration in the midbrain slice cultures (Fig. 3A and B). We confirmed that 50 mM D609 obviously increased exosomal release to the culture media (Fig. 3D). On the other hand, D609 strongly inhibited NO production triggered by IFN-g/LPS (Fig. 3C), because D609 also has the ability to inhibit NOS [22]. Our previous
430
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
Fig. 2. GW4869 protects dopamine neurons from inflammatory degeneration in rat midbrain slice cultures. A. Representative images of TH immunoreactivity on midbrain slice cultures. Slices were cultured under the control conditions or treated with IFN-g/LPS in the presence or absence of GW4869 (1 or 10 mM). Scale bars, 100 mm. B, C. Effects of GW4869 on IFN-g/LPS-induced changes in the number of viable dopamine neurons (B) and nitrite concentration in the culture media (C). ***p < 0.001 vs control, #p < 0.05 (n ¼ 5e6 in B, n ¼ 7 in C). D. Immunoblot analysis of exosomal markers CD63 and flotillin-2) in isolated exosomal lysates from the culture media of midbrain slice cultures. Slices were treated with IFN-g/LPS in the presence or absence of GW4869 (1 or 10 mM). E, F. Representative images of Iba 1 (E) and iNOS (F) immunoreactivities for midbrain slice cultures. Slices were cultured under the control conditions or treated with IFN-g/LPS in the presence or absence of GW4869 (1 or 10 mM). Scale bars, 50 mm. G,H. Effects of GW4869 on IFN-g/LPS-induced changes in the immunoreactivities of Iba 1 (G) and iNOS (H). *p < 0.05, **p < 0.01, ***p < 0.001 vs control (n ¼ 4).
report revealed that the inhibition of NO production prevents dopaminergic degeneration [9]. Taken together, the protective effect by NOS inhibition would be counteracted by the enhancement of exosomal release, resulting in no effect of D609 on dopaminergic neurodegeneration in midbrain slice culture. These findings strongly suggest that exosomes released from activated microglia contribute to dopaminergic neurodegeneration. To validate this concept, we investigated the effect of adding isolated exosomes from microglia-activated slices to dopamine neurons. We treated isolated exosomes from 9 wells of culture media to a single well of midbrain slice cultures. Exosome-C
(exosomes from culture media in control condition) did not affect the number of TH-positive dopamine neurons in midbrain slice culture (Fig. 4A, second image, and 4C). However, exosome-I/L (exosomes from culture media treated with IFN-g/LPS) significantly decreased the number of dopamine neurons (Fig. 4A, third image, and 4C) comparable to slices treated with IFN-g/LPS (Fig. 4A, far right image, and 4C). Exosome-I/L did not trigger the morphological changes in Iba 1-positive microglia (Fig. 4B, third image); in contrast, IFN-g/LPS induced morphological changes of microglia to amoeboid shapes (Fig. 4B, far right image). In addition, exosome-I/L did not significantly affect the immunoreactivity of Iba 1, compared
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
431
Fig. 3. D609 does not affect dopaminergic neurodegeneration induced by IFN-g/LPS treatment of rat midbrain slice cultures. A. Representative images of TH immunoreactivity on midbrain slice cultures. Slices were cultured under control conditions or treated with IFN-g/LPS in the presence or absence of D609 (10 or 50 mM). Scale bars, 100 mm. B, C. Effects of D609 on IFN-g/LPS-induced changes in the number of viable dopamine neurons (B) and nitrite concentration in the culture media (C). **p < 0.01, ***p < 0.001 vs control, ##p < 0.01, ###p < 0.001 (n ¼ 5e6 in B, n ¼ 6 in C). D. Immunoblot analysis of exosomal marker levels (CD63 and flotillin-2) in isolated exosomal lysates from the culture media of midbrain slice cultures. Slices were treated with IFN-g/LPS in the presence or absence of D609 (10 or 50 mM).
Fig. 4. Exosomes from slices treated with IFN-g/LPS induce neurodegeneration of dopamine neurons in midbrain slice cultures. A, B. Representative images of TH (A) and Iba 1(B) immunoreactivities for midbrain slice cultures. Slices were cultured under control conditions, treatment with exosome-C, exosome-I/L for 72 h, or treatment with IFN-g/LPS. Scale bars, 100 mm. C,D. Effects of exosome-C (Exo-C), exosome-I/L (Exo-I/L) and IFN-g/LPS (I/L) on the number of viable dopamine neurons (C) and immunoreactivity of Iba 1 (D). *p < 0.05, **p < 0.01 vs control (Cont), #p < 0.05 (n ¼ 3).
with control slices, while IFN-g/LPS significantly elevated its immunoreactivity (Fig. 4D). These results suggest that exosome-I/L triggers the loss of dopamine neurons without the induction of microglial activation. Taken together, our present findings indicate that exosomes from activated microglia can directly induce dopaminergic neurodegeneration in midbrain slice cultures. In this study, we could not determine how the exosomes from activated microglia induce dopaminergic neurodegeneration. It has been reported that the amount and composition of exosomes are different in patients with neurodegenerative disease relative to
healthy individuals [23], suggesting the possibility that miRNA is involved in the pathogenesis of neurodegenerative diseases. Global analyses of miRNAs revealed that several miRNAs are elevated in the brain of patients with PD [24]. Among them, miR-26b, miR106a, miR-224, miR-373 and miR-379 decreased heat shock cognate protein 70 (Hsc70) and lysosome-associated membrane protein 2a (LAMP2A), which are the mediators of chaperonemediated autophagy (CMA) and reduced CMA activity [25]. CMA is known to degrade a-synuclein, and its impairment triggers the accumulation of a-synuclein [26]. Indeed, Hsc70 is decreased in
432
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
patients with sporadic PD [27]. In addition, shRNA-mediated knockdown of LAMP2A triggers dopaminergic neurodegeneration in the SNpc [28]. Taken together, it is possible that the activated microglia release exosomes containing these miRNA, leading to the dopaminergic neurodegeneration through the impairment of CMA. To investigate the alteration of miRNAs in response to IFN-g/LPS would reveal the molecular mechanism of dopaminergic neurodegeneration. In various neurodegenerative diseases, the formation of inclusion bodies is commonly observed, and these inclusion bodies contain misfolded proteins [29]. Neurons with inclusion bodies are widespread in association with disease progression. This is mediated by the intracellular propagation of misfolded proteins [30]. Exosomes are thought to be involved in this propagation and related to the progression of neurodegenerative diseases [31]. Here, we revealed that exosomes could trigger neurodegeneration. Microglial activation frequently precedes the occurrence of symptoms and neurodegeneration in mouse models of neurodegenerative diseases [32]. Therefore, our present findings provide new insight that exosomes from activated microglia are related to the pathogenesis of neurodegenerative diseases. Exosomes could be a novel molecular target for therapeutics and preventive methods for neurodegenerative diseases. Abbreviations PD SNpc MPTP IFN-g LPS NO NOS miRNA DIV TH GFAP iNOS TLR4 Hsc70 LAMP2A CMA
Parkinson's disease substantia nigra pars compacta 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine interferon-g lipopolysaccharide nitric oxide nitric oxide synthase micro RNA days in vitro tyrosine hydroxylase glial fibrillary acidic protein inducible NOS toll-like receptor 4 heat shock cognate protein 70 lysosome-associated membrane protein 2a chaperone-mediated autophagy
Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrc.2019.02.076. Transparency document Transparency document related to this article can be found online at https://doi.org/10.1016/j.bbrc.2019.02.076. Funding This work was supported by Takeda Science Foundation; Suzuken Memorial Foudation; JSPS KAKENHI, MEXT, Japan [Grants 16K08276]; and the Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Glocal Oriented), MEXT, Japan. References [1] S. Fahn, D. Sulzer, Neurodegeneration and neuroprotection in Parkinson disease, NeuroRx 1 (2004) 139e154, https://doi.org/10.1602/neurorx.1.1.139.
[2] W. Dauer, S. Przedborski, Parkinson's disease: mechanisms and models, Neuron 39 (2003) 889e909, https://doi.org/10.1016/S0896-6273(03)00568-3. [3] B. Thomas, M. Flint Beal, Parkinson's disease, Hum. Mol. Genet. 16 (2007) 183e194, https://doi.org/10.1093/hmg/ddm159. [4] L.M. Collins, A. Toulouse, T.J. Connor, Y.M. Nolan, Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease, Neuropharmacology 62 (2012) 2153e2167, https://doi.org/10.1016/ j.neuropharm.2012.01.028. [5] K.J. Doorn, T. Moors, B. Drukarch, W. Berg, P.J. Lucassen, A.M. Dam, Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson inverted question marks disease patients, Acta Neuropathol Commun 2 (2014) 1e17. [6] S.H. Snyder, R.J. D'Amato, MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture, Neurology 36 (1986) 250e258. http://www.ncbi.nlm.nih.gov/pubmed/3080696. [7] I. Kurkowska-jastrze, A. Wron, The inflammatory reaction following, Exp. Neurol. 156 (1999) 50e61. [8] Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L.G. Nelson, S. Luecke, L.A. Phebus, F.P. Bymaster, S.M. Paul, Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease, Proc. Natl. Acad. Sci. Unit. States Am. 98 (2001) 14669e14674, https://doi.org/10.1073/pnas.251341998. [9] H. Shibata, H. Katsuki, M. Nishiwaki, T. Kume, S. Kaneko, A. Akaike, Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin, J. Neurochem. 86 (2003) 1201e1212, https://doi.org/10.1046/j.14714159.2003.01929.x. [10] J. Meldolesi, Exosomes and ectosomes in intercellular communication, Curr. Biol. 28 (2018) R435eR444, https://doi.org/10.1016/j.cub.2018.01.059. €hlich, W.P. Kuo, E.-M. Kra €mer-Albers, Extracellular vesicles [11] C. Frühbeis, D. Fro as mediators of neuron-glia communication, Front. Cell. Neurosci. 7 (2013) 1e6, https://doi.org/10.3389/fncel.2013.00182. [12] A. Stuendl, M. Kunadt, N. Kruse, C. Bartels, W. Moebius, K.M. Danzer, B. Mollenhauer, A. Schneider, Induction of a-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies, Brain 139 (2016) 481e494, https://doi.org/10.1093/brain/ awv346. [13] T. Takenouchi, M. Tsukimoto, Y. Iwamaru, S. Sugama, K. Sekiyama, M. Sato, S. Kojima, M. Hashimoto, H. Kitani, Extracellular ATP induces unconventional release of glyceraldehyde-3-phosphate dehydrogenase from microglial cells, Immunol. Lett. 167 (2015) 116e124, https://doi.org/10.1016/ j.imlet.2015.08.002. [14] C. Chang, H. Lang, N. Geng, J. Wang, N. Li, X. Wang, Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD, Neurosci. Lett. 548 (2013) 190e195, https://doi.org/10.1016/ j.neulet.2013.06.009. [15] K. Kiyofuji, Y. Kurauchi, A. Hisatsune, T. Seki, S. Mishima, H. Katsuki, A natural compound macelignan protects midbrain dopaminergic neurons from inflammatory degeneration via microglial arginase-1 expression, Eur. J. Pharmacol. 760 (2015), https://doi.org/10.1016/j.ejphar.2015.04.021. [16] S. Takahashi, A. Hisatsune, Y. Kurauchi, T. Seki, H. Katsuki, Polysulfide protects midbrain dopaminergic neurons from MPPþ-induced degeneration via enhancement of glutathione biosynthesis, J. Pharmacol. Sci. 137 (2018) 47e54, https://doi.org/10.1016/j.jphs.2018.04.004. ry, G. Amigorena, A. Raposo, Clayton, isolation and charac[17] C. Thierry, S. The terization of exosomes from cell culture supernatants, Curr. Protoc. Cell Biol. (2006) 1e29, https://doi.org/10.1002/0471143030.cb0322s30 (Chapter 3). [18] T. Seki, L. Gong, A.J. Williams, N. Sakai, S.V. Todi, H.L. Paulson, JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis, J. Biol. Chem. 288 (2013) 17145e17155, https://doi.org/10.1074/jbc.M113.463406. [19] M. Bsibsi, R. Ravid, D. Gveric, J.M. van Noort, Broad expression of toll-like receptors in the human central nervous system, J. Neuropathol. Exp. Neurol. 61 (2002) 1013e1021, https://doi.org/10.1093/jnen/61.11.1013. [20] K. Trajkovic, C. Hsu, S. Chiantia, L. Rajendran, D. Wenzel, F. Wieland, P. Schwille, B. Brügger, M. Simons, Ceramide triggers budding of exosome vesicles into multivesicular endosomes, Science (80-. ) 319 (2007) 1244e1247, https://doi.org/10.1126/science.1152505. [21] K. Yuyama, H. Sun, S. Mitsutake, Y. Igarashi, Sphingolipid-modulated exosome secretion promotes clearance of amyloid-b by microglia, J. Biol. Chem. 287 (2012) 10977e10989, https://doi.org/10.1074/jbc.M111.324616. [22] K. Tschaikowsky, M. Meisner, F. Schonhuber, E. Rugheimer, Induction of nitric oxide synthase activity in phagocytic cells inhibited by tricyclodecan-9-ylxanthogenate (D609), Br. J. Pharmacol. 113 (1994) 664e668. http://www. ncbi.nlm.nih.gov/htbin-post/Entrez/query? db¼m&form¼6&dopt¼r&uid¼7532078. [23] E.F. Goodall, P.R. Heath, O. Bandmann, J. Kirby, P.J. Shaw, Neuronal dark matter: the emerging role of microRNAs in neurodegeneration, Front. Cell. Neurosci. 7 (2013) 1e16, https://doi.org/10.3389/fncel.2013.00178. [24] J. Kim, K. Inoue, J. Ishii, W.B. Vanti, S.V. Voronov, E. Murchison, G. Hannon, A. Abeliovich, A microRNA feedback circuit in midbrain dopamine neurons, Science (80-. ) 317 (2007) 1220e1224, https://doi.org/10.1126/ science.1140481. [25] L. Alvarez-Erviti, Y. Seow, A.H.V. Schapira, M.C. Rodriguez-Oroz, J.A. Obeso, J.M. Cooper, Influence of microRNA deregulation on chaperone-mediated
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433 autophagy and a-synuclein pathology in Parkinson's disease, Cell Death Dis. 4 (2013) e545ee548, https://doi.org/10.1038/cddis.2013.73. [26] A.M. Cuervo, L. Stefanis, R. Fredenburg, P.T. Lansbury, D. Sulzer, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy, Science 305 (2004) 1292e1295, https://doi.org/10.1126/science.1101738. [27] G. Sala, G. Stefanoni, A. Arosio, C. Riva, L. Melchionda, E. Saracchi, S. Fermi, L. Brighina, C. Ferrarese, Reduced expression of the chaperone-mediated autophagy carrier hsc70 protein in lymphomonocytes of patients with Parkinson's disease, Brain Res. 1546 (2014) 46e52, https://doi.org/10.1016/ j.brainres.2013.12.017. [28] M. Xilouri, O.R. Brekk, A. Polissidis, M. Chrysanthou-Piterou, I. Kloukina, L. Stefanis, Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats, Autophagy 12 (2016) 2230e2247, https://
433
doi.org/10.1080/15548627.2016.1214777. [29] C.A. Ross, M.A. Poirier, Protein aggregation and neurodegenerative disease, Nat. Med. 10 (2004) S10, https://doi.org/10.1038/nm1066. [30] B.E. Stopschinski, M.I. Diamond, The prion model for progression and diversity of neurodegenerative diseases, Lancet Neurol. 16 (2017) 323e332, https:// doi.org/10.1016/S1474-4422(17)30037-6. [31] J. Howitt, A.F. Hill, Exosomes in the pathology of neurodegenerative diseases, J. Biol. Chem. 291 (2016) 26589e26597, https://doi.org/10.1074/ jbc.R116.757955. [32] C. Schwab, A. Klegeris, P.L. McGeer, Inflammation in transgenic mouse models of neurodegenerative disorders, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1802 (2010) 889e902, https://doi.org/10.1016/j.bbadis.2009.10.013.
Contents lists available at ScienceDirect
Biochemical and Biophysical Research Communications journal homepage: www.elsevier.com/locate/ybbrc
Involvement of exosomes in dopaminergic neurodegeneration by microglial activation in midbrain slice cultures Reiho Tsutsumi a, Yuria Hori a, Takahiro Seki a, *, Yuki Kurauchi a, Masahiro Sato a, Mutsumi Oshima a, Akinori Hisatsune b, c, Hiroshi Katsuki a a
Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan Priority Organization for Innovation and Excellence, Kumamoto University, Kumamoto, Japan Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Glocal Oriented) Program”, Kumamoto University, Kumamoto, Japan b c
a r t i c l e i n f o
a b s t r a c t
Article history: Received 8 February 2019 Accepted 14 February 2019 Available online 23 February 2019
Parkinson's disease (PD) is a neurodegenerative disorder characterized by the progressive degeneration of dopamine neurons in the substantia nigra. Microglial activation is frequently observed in the brains of patients with PD and animal models. Interferon-g (IFN-g)/lipopolysaccharide (LPS) treatment triggers microglial activation and the reduction of dopamine neurons in midbrain slice cultures. We have previously reported that nitric oxide (NO) is mainly involved in this dopaminergic degeneration. However, this degeneration was not completely suppressed by the inhibition of NO synthesis, suggesting that factors other than NO also contribute to dopaminergic neurodegeneration. Exosomes are extracellular vesicles with diameters of 40e200 nm that contain various proteins and micro RNAs and are regarded as a novel factor that mediates cell-to-cell interactions. Previous studies have demonstrated that exosome release is enhanced by microglial stimulation and that microglia-derived exosomes increases neuronal apoptosis. In the present study, we investigated whether exosomes are involved in dopaminergic neurodegeneration triggered by microglial activation in midbrain slice cultures. IFN-g/LPS treatment to the midbrain slice cultures activated microglia, increased exosomal release, and decreased dopamine neurons. GW4869, an inhibitor of a neutral sphingomyelinase 2, decreased exosomal release and significantly prevented dopaminergic neurodegeneration by IFN-g/LPS without affecting NO production. In contrast, D609, an inhibitor of sphingomyelin synthase and NO synthase, did not affect dopaminergic neurodegeneration, although it strongly inhibited NO production. The protective effect mediated by inhibition of NO synthase would be counteracted by enhanced exosomal release caused by D609 treatment. In addition, dopaminergic neurodegeneration is triggered by the treatment of exosomes isolated from culture media of IFN-g/LPS-treated slices. These results suggest that exosomes are involved in dopaminergic neurodegeneration by microglial activation. © 2019 Elsevier Inc. All rights reserved.
Keywords: Parkinson's disease Dopamine neuron Microglia Exosomes
1. Introduction Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by severe motor dysfunctions such as bradykinesia, resting tremor, and rigidity [1,2]. These dysfunctions are caused by the progressive and selective degeneration of dopamine neurons in the midbrain substantia nigra pars compacta (SNpc)
* Corresponding author. Department of Chemico-Pharmacological Sciences, Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 OeHonmachi, Chuo-ku, Kumamoto, 862-0973, Japan. E-mail address: [email protected] (T. Seki). https://doi.org/10.1016/j.bbrc.2019.02.076 0006-291X/© 2019 Elsevier Inc. All rights reserved.
[1e3]. Although various environmental and genetic factors are reported to be involved in PD pathogenesis [1e3], it has not been fully elucidated how the dopamine neurons are selectively degenerated in PD. Inflammation is considered to be involved in dopaminergic neurodegeneration because the accumulation of reactive microglia frequently occurs in the SNpc of patients with PD [4,5]. 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin specific for dopamine neurons, reduces dopamine neurons in SNpc, and induces the motor dysfunction like parkinsonism of PD patients in mice and rats [6]. MPTP treatment induces the accumulation of activated microglia in SNpc [7], and the neurotoxic effect of MPTP is
428
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
reduced by the inhibition of microglial activation [8]. We have previously demonstrated that microglial activation by interferon-g (IFN-g) and lipopolysaccharide (LPS) induced dopaminergic degeneration in the SNpc of midbrain slice cultures [9]. Nitric oxide (NO), generated from the activated microglia, contributes to the dopaminergic neurodegeneration, because an inhibitor of nitric oxide synthase (NOS) significantly prevented this degeneration [9]. However, although the NOS inhibitor almost completely blocked NO synthesis from the activated microglia, it did not completely prevent dopaminergic neurodegeneration. Therefore, it is possible that other factors in addition to NO contribute to dopaminergic neurodegeneration by microglial activation. Exosomes are extracellular vesicles with diameters of 40e200 nm, which contain various proteins and micro RNAs (miRNAs) and participate in intercellular communication [10]. Notably, exosomes are considered to be involved in neuron-glia communication in the brain [11]. Exosomes are elevated in the cerebrospinal fluids of patients with PD [12]. In addition, microglial activation increases exosome release from MG6 microglial cells [13]. Moreover, exosomes from a-synuclein-treated microglial cells have a cytotoxic effect when added to primary cultured neural cells [14]. Taken together, we predicted that exosomes from the activated microglia contribute to dopaminergic neurodegeneration in the midbrain slice cultures. To validate this hypothesis, we investigated the effects of the chemicals that affect the production of exosomes in dopaminergic neurodegeneration induced by microglial activation. 2. Materials and methods 2.1. Preparation of midbrain slice cultures All animal experimental procedures were approved by the Kumamoto University Ethics Committee on Animal Experiments, and animals were handled according to the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize animal suffering and to reduce the number of animals used. Organotypic slice cultures of the rat midbrain were prepared as described in our previous studies [15,16]. Briefly, coronal midbrain slices (350-mm thick) were prepared from 2 or 3 day-old neonatal Wistar rats (Nihon SLC, Shizuoka, Japan) and were transferred onto microporous membranes (Millicell-CM, Merck Millipore, Darmstadt, Germany) in six-well plates. Culture medium, consisting of 50% minimum essential medium/HEPES, 25% Hanks' balanced salt solution and 25% heat-inactivated horse serum supplemented with 6.5 mg/mL glucose, 2 mM L-glutamine, and 10 U/mL penicillin-G plus 10 mg/mL streptomycin, was supplied at a volume of 0.7 mL per well. The culture medium was exchanged with fresh medium on the next day of culture preparation, and thereafter, every 3 day. Slices were maintained in a 34 C, 5% CO2 humidified atmosphere for 20 days in vitro (DIV). For immunohistochemistry experiments, slices were fixed with 4% paraformaldehyde in 0.1 M phosphate buffer containing 4% sucrose at 4 C for 2.5 h. Culture media samples were collected for exosome isolation and nitrite quantification.
were simultaneously treated with IFN-g and LPS for 96 h. 2.3. Isolation and detection of exosomes from the culture media Isolation of exosomes was conducted following a modified method from a previous report [17]. Culture media from 3 to 6 independent experiments were centrifuged at 2000g for 10 min at 4 C to precipitate the cell debris. The supernatant was collected and filtrated through a 0.2 mm filter to remove particles larger than 220 nm. The filtered supernatant was ultracentrifuged at 100,000g for 70 min at 4 C using an Avanti HP-30I (Beckman Coulter, Brea, CA, USA) to precipitate the exosomes. After removing the supernatant, pellets were resuspended in PBS and ultracentrifuged at 100,000g for 70 min at 4 C. For immunoblotting, the pellets were resuspended in sample buffer containing 0.5 M of Tris-HCl (pH 6.8), 10% SDS, 5 mM of dithiothreitol, 10% glycerol, and 1% bromophenol blue, followed by heating at 100 C for 15 min. For treatment of the other slices, the pellets were resuspended in serum-free culture media. Exosomes from 9 wells of culture media from control condition (exosome-C) or IFN-g/LPS-treated culture media (exosome-I/L) were added to the other slice cultures for 72 h (from DIV 18e20). 2.4. Immunohistochemistry Immunohistochemical examinations were performed according to previously described methods [15,16]. Cultured slices were incubated for 1 h at room temperature with PBS containing 0.3% Triton X-100 and 3% normal donkey serum for permeabilization and blocking. Thereafter, slices were incubated overnight at 4 C with a primary antibody solution in PBS containing 0.3% Triton X100 and 3% normal donkey serum. Primary antibodies were antityrosine hydroxylase (TH) mouse monoclonal antibody (1:500; Millipore, Burlington, MA, USA), anti-TH rabbit polyclonal antibody (1:500; Millipore), anti-Iba 1 rabbit polyclonal antibody (1:400; H070e47; Wako Chemicals, Osaka, Japan), anti-glial fibrillary acidic protein (GFAP) goat polyclonal antibody (1:500, Santa Cruz Biotechnology, Dallas, TX, USA), and anti-iNOS mouse monoclonal antibody (1:500, BD Biosciences, San Jose, CA, USA). After 3 washes with PBS, slices were incubated for 1 h at room temperature in Alexa Fluor 488- or Alexa Fluor 555-conjugated secondary antibodies (1:500; Thermo Fisher Scientific) in PBS containing 0.3% Triton X-100 and 3% normal donkey serum. Fluorescent images of immunostained slices were obtained using a fluorescence microscope (BIOREVO, Keyence, Osaka, Japan) or a confocal laser microscope (TCS SP5, Leica Biosystems, Nussloch, Germany). Immunoreactivities of Iba 1 and iNOS in fluorescent images were quantified using LAS AF Lite software (Leica Biosystems). 2.5. Immunoblotting Equal volumes of exosomal lysates were subjected to SDS-PAGE, followed by immunoblot analyses as described in our previous study [18] using anti-CD63 mouse monoclonal antibody (1:500; Bio-Rad Laboratories, Hercules, CA, USA) and anti-flotillin-2 mouse monoclonal antibody (1:1000; BD Biosciences).
2.2. Drug treatment 2.6. Nitrite quantification Rat interferon (IFN)-g (PeproTech, Rocky Hill, NJ, USA) and LPS (from Escherichia coli, serotype 0111; B4; Sigma, St Louis, MO, USA) were used to activate microglia in slice cultures [15]. From DIV 17e20, midbrain slice cultures were treated with IFN-g (50 ng/mL) for 24 h, followed by LPS (10 ng/mL) treatment for 72 h. GW4869 (1 or 10 mM, Sigma), an inhibitor of neutral sphingomyelinase 2, and D609 (10 or 50 mM, Sigma), an inhibitor of sphingomyelin synthase,
A colorimetric Griess assay was employed to determine the concentration of nitrite in the culture medium, which reflects the amount of NO released from cultured tissues. Culture supernatants were reacted with an equal volume of Griess reagent (Sigma) for 10 min at room temperature, and the amount of diazonium compound was determined based on the absorbance at a wavelength of
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
560 nm. 2.7. Statistical analyses All quantitative data are represented as the mean ± SEM. Statistical differences were determined by one-way ANOVA, followed by a post hoc test (Tukey method). Probability values less than 0.05 were considered significant. 3. Results and discussion Exosomes are known to be released from both neurons and glial cells and to be involved in neuron-glia communication [11]. We first examined whether inflammatory stimulation affected exosomal release in midbrain slice cultures. Treatment with IFN-g and LPS prominently increased exosome marker levels (CD63 and flotillin-2) in exosomal lysates from the culture media of midbrain slice cultures (Fig. 1A). This treatment induced microglial activation, which was characterized by increased Iba1 immunoreactivity and morphological changes of microglia to amoeboid shapes in midbrain slice cultures (Fig. 1B), consistent with our previous study
Fig. 1. IFN-g/LPS treatment triggers exosome release and microglial activation in rat midbrain slice cultures. A. Immunoblot analysis of exosomal markers (CD63 and flotillin-2) in isolated exosomal lysates from the culture media of midbrain slice cultures. Slices were cultured under the control conditions or treated with 50 ng/mL IFN-g for 24 h followed by 10 mg/mL LPS for 72 h. B, C. Representative images of Iba 1 (B) and GFAP (C) immunoreactivities on the cultured midbrain slices. Slices were cultured under control conditions or treated with IFN-g/LPS. Scale bars, 50 mm.
429
[9]. On the other hand, GFAP immunoreactivity was not affected by IFN-g/LPS (Fig. 1C). Although astrocytes also express toll-like receptor 4 (TLR4), a receptor for LPS, the level of TLR4 is lower in astrocytes than in microglia [19]. Taken together, astrocytes were not activated by these stimuli. In addition, minocycline, which inhibits microglial activation, decreased the level of exosomal markers (Supplemental Fig. 1A). Taken together, although we could not exclude the possibility that an increase in exosomes partly comes from neurons, we found that treatment of midbrain slice cultures with IFN-g/LPS resulted in an increase in exosomal release, mainly from the activated microglia. This is consistent with a previous report that stimulation with exogenous ATP triggers an increase in exosomal release from MG6 cells, a cell line derived from microglia [13]. We next examined the effects of pharmacological alteration of exosomal release on IFN-g/LPS-induced dopaminergic neurodegeneration. Exosomal production is regulated by ceramide synthesis in multivesicular bodies [20]. G4869 is an inhibitor of neutral sphingomyelinase 2, which decreases ceramide synthesis from sphingomyelin and inhibits the production and release of exosomes [20]. We simultaneously treated midbrain slice cultures with GW4869 (1 or 10 mM) and IFN-g/LPS to examine dopaminergic neurodegeneration in the SNpc. Tyrosine hydroxylase (TH)-positive dopamine neurons in SNpc were significantly decreased after treatment with IFN-g/LPS (Fig. 2A and B), consistent with our previous studies [9]. Concomitant treatment of GW4869 significantly prevented the reduction of dopamine neurons by IFN-g/LPS (Fig. 2A and B). IFN-g/LPS-triggered production of nitric oxide (NO) was not significantly affected by GW4869, whereas treatment with 10 mM GW4869 slightly decreased this production (Fig. 2C). On the other hand, exosomal release to the culture media was strikingly impaired by GW4869 (Fig. 2D). Because inhibition of microglial activation by minocycline decreased exosomal release and dopaminergic neurodegeneration triggered by IFN-g/LPS (Supplemental Fig. 2), the inhibition of dopaminergic neurodegeneration by GW4869 might be caused by an inhibition of microglial activation. However, the elevated immunoreactivity of Iba 1 and the morphological changes in Iba 1-positive microglia by IFN-g/LPS treatment were not affected by GW4869 (Fig. 2E, G). Likewise, the elevated immunoreactivity of inducible nitric oxide synthase (iNOS), a marker of inflammatory activation of microglia, were not affected by GW4869 (Fig. 2F, H). In addition, GW4869 prevented exosomal release to the culture media, but did not affect the elevation of inflammatory cytokine mRNAs in a microglial cell line (BV2 cells) (Supplemental Fig. 1), suggesting that GW4869 did not inhibit microglial activation through IFN-g/LPS. Another possibility is that GW4869 directly affects neurons to protect cells from inflammatory stimuli. However, we found that GW4869 triggered a significant decrease of TH-positive dopamine neurons in midbrain primary cultures (Supplemental Fig. 3). These findings suggest that the protective effect of GW4869 on dopamine neurons is mediated by the prevention of exosomal release from activated microglia. To further investigate the involvement of exosomes in dopaminergic neurodegeneration induced by microglial activation, we examined the effect of a chemical that enhances exosomal release. D609 is an inhibitor of sphingomyelin synthase, which catalyzes the conversion of ceramide to sphingomyelin, induces the accumulation of ceramide, and enhances the production and release of exosomes [21]. Concomitant treatment of D609 (10 or 50 mM) with IFN-g/LPS neither prevented nor exacerbated the dopaminergic neurodegeneration in the midbrain slice cultures (Fig. 3A and B). We confirmed that 50 mM D609 obviously increased exosomal release to the culture media (Fig. 3D). On the other hand, D609 strongly inhibited NO production triggered by IFN-g/LPS (Fig. 3C), because D609 also has the ability to inhibit NOS [22]. Our previous
430
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
Fig. 2. GW4869 protects dopamine neurons from inflammatory degeneration in rat midbrain slice cultures. A. Representative images of TH immunoreactivity on midbrain slice cultures. Slices were cultured under the control conditions or treated with IFN-g/LPS in the presence or absence of GW4869 (1 or 10 mM). Scale bars, 100 mm. B, C. Effects of GW4869 on IFN-g/LPS-induced changes in the number of viable dopamine neurons (B) and nitrite concentration in the culture media (C). ***p < 0.001 vs control, #p < 0.05 (n ¼ 5e6 in B, n ¼ 7 in C). D. Immunoblot analysis of exosomal markers CD63 and flotillin-2) in isolated exosomal lysates from the culture media of midbrain slice cultures. Slices were treated with IFN-g/LPS in the presence or absence of GW4869 (1 or 10 mM). E, F. Representative images of Iba 1 (E) and iNOS (F) immunoreactivities for midbrain slice cultures. Slices were cultured under the control conditions or treated with IFN-g/LPS in the presence or absence of GW4869 (1 or 10 mM). Scale bars, 50 mm. G,H. Effects of GW4869 on IFN-g/LPS-induced changes in the immunoreactivities of Iba 1 (G) and iNOS (H). *p < 0.05, **p < 0.01, ***p < 0.001 vs control (n ¼ 4).
report revealed that the inhibition of NO production prevents dopaminergic degeneration [9]. Taken together, the protective effect by NOS inhibition would be counteracted by the enhancement of exosomal release, resulting in no effect of D609 on dopaminergic neurodegeneration in midbrain slice culture. These findings strongly suggest that exosomes released from activated microglia contribute to dopaminergic neurodegeneration. To validate this concept, we investigated the effect of adding isolated exosomes from microglia-activated slices to dopamine neurons. We treated isolated exosomes from 9 wells of culture media to a single well of midbrain slice cultures. Exosome-C
(exosomes from culture media in control condition) did not affect the number of TH-positive dopamine neurons in midbrain slice culture (Fig. 4A, second image, and 4C). However, exosome-I/L (exosomes from culture media treated with IFN-g/LPS) significantly decreased the number of dopamine neurons (Fig. 4A, third image, and 4C) comparable to slices treated with IFN-g/LPS (Fig. 4A, far right image, and 4C). Exosome-I/L did not trigger the morphological changes in Iba 1-positive microglia (Fig. 4B, third image); in contrast, IFN-g/LPS induced morphological changes of microglia to amoeboid shapes (Fig. 4B, far right image). In addition, exosome-I/L did not significantly affect the immunoreactivity of Iba 1, compared
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
431
Fig. 3. D609 does not affect dopaminergic neurodegeneration induced by IFN-g/LPS treatment of rat midbrain slice cultures. A. Representative images of TH immunoreactivity on midbrain slice cultures. Slices were cultured under control conditions or treated with IFN-g/LPS in the presence or absence of D609 (10 or 50 mM). Scale bars, 100 mm. B, C. Effects of D609 on IFN-g/LPS-induced changes in the number of viable dopamine neurons (B) and nitrite concentration in the culture media (C). **p < 0.01, ***p < 0.001 vs control, ##p < 0.01, ###p < 0.001 (n ¼ 5e6 in B, n ¼ 6 in C). D. Immunoblot analysis of exosomal marker levels (CD63 and flotillin-2) in isolated exosomal lysates from the culture media of midbrain slice cultures. Slices were treated with IFN-g/LPS in the presence or absence of D609 (10 or 50 mM).
Fig. 4. Exosomes from slices treated with IFN-g/LPS induce neurodegeneration of dopamine neurons in midbrain slice cultures. A, B. Representative images of TH (A) and Iba 1(B) immunoreactivities for midbrain slice cultures. Slices were cultured under control conditions, treatment with exosome-C, exosome-I/L for 72 h, or treatment with IFN-g/LPS. Scale bars, 100 mm. C,D. Effects of exosome-C (Exo-C), exosome-I/L (Exo-I/L) and IFN-g/LPS (I/L) on the number of viable dopamine neurons (C) and immunoreactivity of Iba 1 (D). *p < 0.05, **p < 0.01 vs control (Cont), #p < 0.05 (n ¼ 3).
with control slices, while IFN-g/LPS significantly elevated its immunoreactivity (Fig. 4D). These results suggest that exosome-I/L triggers the loss of dopamine neurons without the induction of microglial activation. Taken together, our present findings indicate that exosomes from activated microglia can directly induce dopaminergic neurodegeneration in midbrain slice cultures. In this study, we could not determine how the exosomes from activated microglia induce dopaminergic neurodegeneration. It has been reported that the amount and composition of exosomes are different in patients with neurodegenerative disease relative to
healthy individuals [23], suggesting the possibility that miRNA is involved in the pathogenesis of neurodegenerative diseases. Global analyses of miRNAs revealed that several miRNAs are elevated in the brain of patients with PD [24]. Among them, miR-26b, miR106a, miR-224, miR-373 and miR-379 decreased heat shock cognate protein 70 (Hsc70) and lysosome-associated membrane protein 2a (LAMP2A), which are the mediators of chaperonemediated autophagy (CMA) and reduced CMA activity [25]. CMA is known to degrade a-synuclein, and its impairment triggers the accumulation of a-synuclein [26]. Indeed, Hsc70 is decreased in
432
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433
patients with sporadic PD [27]. In addition, shRNA-mediated knockdown of LAMP2A triggers dopaminergic neurodegeneration in the SNpc [28]. Taken together, it is possible that the activated microglia release exosomes containing these miRNA, leading to the dopaminergic neurodegeneration through the impairment of CMA. To investigate the alteration of miRNAs in response to IFN-g/LPS would reveal the molecular mechanism of dopaminergic neurodegeneration. In various neurodegenerative diseases, the formation of inclusion bodies is commonly observed, and these inclusion bodies contain misfolded proteins [29]. Neurons with inclusion bodies are widespread in association with disease progression. This is mediated by the intracellular propagation of misfolded proteins [30]. Exosomes are thought to be involved in this propagation and related to the progression of neurodegenerative diseases [31]. Here, we revealed that exosomes could trigger neurodegeneration. Microglial activation frequently precedes the occurrence of symptoms and neurodegeneration in mouse models of neurodegenerative diseases [32]. Therefore, our present findings provide new insight that exosomes from activated microglia are related to the pathogenesis of neurodegenerative diseases. Exosomes could be a novel molecular target for therapeutics and preventive methods for neurodegenerative diseases. Abbreviations PD SNpc MPTP IFN-g LPS NO NOS miRNA DIV TH GFAP iNOS TLR4 Hsc70 LAMP2A CMA
Parkinson's disease substantia nigra pars compacta 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine interferon-g lipopolysaccharide nitric oxide nitric oxide synthase micro RNA days in vitro tyrosine hydroxylase glial fibrillary acidic protein inducible NOS toll-like receptor 4 heat shock cognate protein 70 lysosome-associated membrane protein 2a chaperone-mediated autophagy
Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi.org/10.1016/j.bbrc.2019.02.076. Transparency document Transparency document related to this article can be found online at https://doi.org/10.1016/j.bbrc.2019.02.076. Funding This work was supported by Takeda Science Foundation; Suzuken Memorial Foudation; JSPS KAKENHI, MEXT, Japan [Grants 16K08276]; and the Program for Leading Graduate Schools “HIGO (Health Life Science: Interdisciplinary and Glocal Oriented), MEXT, Japan. References [1] S. Fahn, D. Sulzer, Neurodegeneration and neuroprotection in Parkinson disease, NeuroRx 1 (2004) 139e154, https://doi.org/10.1602/neurorx.1.1.139.
[2] W. Dauer, S. Przedborski, Parkinson's disease: mechanisms and models, Neuron 39 (2003) 889e909, https://doi.org/10.1016/S0896-6273(03)00568-3. [3] B. Thomas, M. Flint Beal, Parkinson's disease, Hum. Mol. Genet. 16 (2007) 183e194, https://doi.org/10.1093/hmg/ddm159. [4] L.M. Collins, A. Toulouse, T.J. Connor, Y.M. Nolan, Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease, Neuropharmacology 62 (2012) 2153e2167, https://doi.org/10.1016/ j.neuropharm.2012.01.028. [5] K.J. Doorn, T. Moors, B. Drukarch, W. Berg, P.J. Lucassen, A.M. Dam, Microglial phenotypes and toll-like receptor 2 in the substantia nigra and hippocampus of incidental Lewy body disease cases and Parkinson inverted question marks disease patients, Acta Neuropathol Commun 2 (2014) 1e17. [6] S.H. Snyder, R.J. D'Amato, MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. The 1985 George C. Cotzias lecture, Neurology 36 (1986) 250e258. http://www.ncbi.nlm.nih.gov/pubmed/3080696. [7] I. Kurkowska-jastrze, A. Wron, The inflammatory reaction following, Exp. Neurol. 156 (1999) 50e61. [8] Y. Du, Z. Ma, S. Lin, R.C. Dodel, F. Gao, K.R. Bales, L.C. Triarhou, E. Chernet, K.W. Perry, D.L.G. Nelson, S. Luecke, L.A. Phebus, F.P. Bymaster, S.M. Paul, Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease, Proc. Natl. Acad. Sci. Unit. States Am. 98 (2001) 14669e14674, https://doi.org/10.1073/pnas.251341998. [9] H. Shibata, H. Katsuki, M. Nishiwaki, T. Kume, S. Kaneko, A. Akaike, Lipopolysaccharide-induced dopaminergic cell death in rat midbrain slice cultures: role of inducible nitric oxide synthase and protection by indomethacin, J. Neurochem. 86 (2003) 1201e1212, https://doi.org/10.1046/j.14714159.2003.01929.x. [10] J. Meldolesi, Exosomes and ectosomes in intercellular communication, Curr. Biol. 28 (2018) R435eR444, https://doi.org/10.1016/j.cub.2018.01.059. €hlich, W.P. Kuo, E.-M. Kra €mer-Albers, Extracellular vesicles [11] C. Frühbeis, D. Fro as mediators of neuron-glia communication, Front. Cell. Neurosci. 7 (2013) 1e6, https://doi.org/10.3389/fncel.2013.00182. [12] A. Stuendl, M. Kunadt, N. Kruse, C. Bartels, W. Moebius, K.M. Danzer, B. Mollenhauer, A. Schneider, Induction of a-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies, Brain 139 (2016) 481e494, https://doi.org/10.1093/brain/ awv346. [13] T. Takenouchi, M. Tsukimoto, Y. Iwamaru, S. Sugama, K. Sekiyama, M. Sato, S. Kojima, M. Hashimoto, H. Kitani, Extracellular ATP induces unconventional release of glyceraldehyde-3-phosphate dehydrogenase from microglial cells, Immunol. Lett. 167 (2015) 116e124, https://doi.org/10.1016/ j.imlet.2015.08.002. [14] C. Chang, H. Lang, N. Geng, J. Wang, N. Li, X. Wang, Exosomes of BV-2 cells induced by alpha-synuclein: important mediator of neurodegeneration in PD, Neurosci. Lett. 548 (2013) 190e195, https://doi.org/10.1016/ j.neulet.2013.06.009. [15] K. Kiyofuji, Y. Kurauchi, A. Hisatsune, T. Seki, S. Mishima, H. Katsuki, A natural compound macelignan protects midbrain dopaminergic neurons from inflammatory degeneration via microglial arginase-1 expression, Eur. J. Pharmacol. 760 (2015), https://doi.org/10.1016/j.ejphar.2015.04.021. [16] S. Takahashi, A. Hisatsune, Y. Kurauchi, T. Seki, H. Katsuki, Polysulfide protects midbrain dopaminergic neurons from MPPþ-induced degeneration via enhancement of glutathione biosynthesis, J. Pharmacol. Sci. 137 (2018) 47e54, https://doi.org/10.1016/j.jphs.2018.04.004. ry, G. Amigorena, A. Raposo, Clayton, isolation and charac[17] C. Thierry, S. The terization of exosomes from cell culture supernatants, Curr. Protoc. Cell Biol. (2006) 1e29, https://doi.org/10.1002/0471143030.cb0322s30 (Chapter 3). [18] T. Seki, L. Gong, A.J. Williams, N. Sakai, S.V. Todi, H.L. Paulson, JosD1, a membrane-targeted deubiquitinating enzyme, is activated by ubiquitination and regulates membrane dynamics, cell motility, and endocytosis, J. Biol. Chem. 288 (2013) 17145e17155, https://doi.org/10.1074/jbc.M113.463406. [19] M. Bsibsi, R. Ravid, D. Gveric, J.M. van Noort, Broad expression of toll-like receptors in the human central nervous system, J. Neuropathol. Exp. Neurol. 61 (2002) 1013e1021, https://doi.org/10.1093/jnen/61.11.1013. [20] K. Trajkovic, C. Hsu, S. Chiantia, L. Rajendran, D. Wenzel, F. Wieland, P. Schwille, B. Brügger, M. Simons, Ceramide triggers budding of exosome vesicles into multivesicular endosomes, Science (80-. ) 319 (2007) 1244e1247, https://doi.org/10.1126/science.1152505. [21] K. Yuyama, H. Sun, S. Mitsutake, Y. Igarashi, Sphingolipid-modulated exosome secretion promotes clearance of amyloid-b by microglia, J. Biol. Chem. 287 (2012) 10977e10989, https://doi.org/10.1074/jbc.M111.324616. [22] K. Tschaikowsky, M. Meisner, F. Schonhuber, E. Rugheimer, Induction of nitric oxide synthase activity in phagocytic cells inhibited by tricyclodecan-9-ylxanthogenate (D609), Br. J. Pharmacol. 113 (1994) 664e668. http://www. ncbi.nlm.nih.gov/htbin-post/Entrez/query? db¼m&form¼6&dopt¼r&uid¼7532078. [23] E.F. Goodall, P.R. Heath, O. Bandmann, J. Kirby, P.J. Shaw, Neuronal dark matter: the emerging role of microRNAs in neurodegeneration, Front. Cell. Neurosci. 7 (2013) 1e16, https://doi.org/10.3389/fncel.2013.00178. [24] J. Kim, K. Inoue, J. Ishii, W.B. Vanti, S.V. Voronov, E. Murchison, G. Hannon, A. Abeliovich, A microRNA feedback circuit in midbrain dopamine neurons, Science (80-. ) 317 (2007) 1220e1224, https://doi.org/10.1126/ science.1140481. [25] L. Alvarez-Erviti, Y. Seow, A.H.V. Schapira, M.C. Rodriguez-Oroz, J.A. Obeso, J.M. Cooper, Influence of microRNA deregulation on chaperone-mediated
R. Tsutsumi et al. / Biochemical and Biophysical Research Communications 511 (2019) 427e433 autophagy and a-synuclein pathology in Parkinson's disease, Cell Death Dis. 4 (2013) e545ee548, https://doi.org/10.1038/cddis.2013.73. [26] A.M. Cuervo, L. Stefanis, R. Fredenburg, P.T. Lansbury, D. Sulzer, Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy, Science 305 (2004) 1292e1295, https://doi.org/10.1126/science.1101738. [27] G. Sala, G. Stefanoni, A. Arosio, C. Riva, L. Melchionda, E. Saracchi, S. Fermi, L. Brighina, C. Ferrarese, Reduced expression of the chaperone-mediated autophagy carrier hsc70 protein in lymphomonocytes of patients with Parkinson's disease, Brain Res. 1546 (2014) 46e52, https://doi.org/10.1016/ j.brainres.2013.12.017. [28] M. Xilouri, O.R. Brekk, A. Polissidis, M. Chrysanthou-Piterou, I. Kloukina, L. Stefanis, Impairment of chaperone-mediated autophagy induces dopaminergic neurodegeneration in rats, Autophagy 12 (2016) 2230e2247, https://
433
doi.org/10.1080/15548627.2016.1214777. [29] C.A. Ross, M.A. Poirier, Protein aggregation and neurodegenerative disease, Nat. Med. 10 (2004) S10, https://doi.org/10.1038/nm1066. [30] B.E. Stopschinski, M.I. Diamond, The prion model for progression and diversity of neurodegenerative diseases, Lancet Neurol. 16 (2017) 323e332, https:// doi.org/10.1016/S1474-4422(17)30037-6. [31] J. Howitt, A.F. Hill, Exosomes in the pathology of neurodegenerative diseases, J. Biol. Chem. 291 (2016) 26589e26597, https://doi.org/10.1074/ jbc.R116.757955. [32] C. Schwab, A. Klegeris, P.L. McGeer, Inflammation in transgenic mouse models of neurodegenerative disorders, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis. 1802 (2010) 889e902, https://doi.org/10.1016/j.bbadis.2009.10.013.